Latest Period
Q4 2025
Security Snapshot
Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) Institutional Ownership
CUSIP: 70261F202
13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026
Institutions Reporting
24
Shares (Excl. Options)
12,892,082
Price
$1.29
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001
- Symbol
- KTTA on Nasdaq
- Shares outstanding
- 24,858,270
- Price per share
- $0.76
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 12,892,082
- Total reported value
- $16,641,289
- % of total 13F portfolios
- 0%
- Share change
- +10,180,078
- Value change
- +$13,193,231
- Number of holders
- 24
- Price from insider filings
- $0.76
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 is tracked under CUSIP 70261F202.
- 24 institutions reported positions in Q4 2025.
- 13 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 24 to 2 between Q4 2025 and Q1 2026.
- Reported value moved from $16,641,289 to $251,143.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 24 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 70261F202?
CUSIP 70261F202 identifies KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 70261F202:
Significant Owners of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | $12,292,327 | 17,560,467 | Vivo Opportunity Fund Holdings, L.P. | 01 Dec 2025 | |||
| JANUS HENDERSON GROUP PLC | 10% | $7,160,756 | 10,229,652 | JANUS HENDERSON GROUP PLC | 28 Nov 2025 | |||
| Opaleye Management Inc. | 10% | $2,092,440 | 2,491,000 | Opaleye Management Inc. | 01 Apr 2026 | |||
| Coastlands Capital LP | 10% | $2,059,498 | 2,394,765 | Coastlands Capital LP | 23 Feb 2026 | |||
| Adage Capital Management, L.P. | 10% | $2,050,179 | 2,329,749 | Adage Capital Management, L.P. | 31 Dec 2025 | |||
| Squadron Capital Management LLC | 9.9% | 0% | $2,050,179 | +$67,601 | 2,329,749 | +3.4% | Squadron Master Fund LP | 31 Dec 2025 |
| AMERIPRISE FINANCIAL INC | 8.4% | $1,698,513 | 1,930,128 | Ameriprise Financial, Inc. | 31 Dec 2025 | |||
| Funicular Funds, LP | 7.4% | $1,416,424 | 1,839,512 | Funicular Funds, LP | 15 Apr 2026 | |||
| CVI Investments, Inc. | 3.8% | -61% | $791,995 | +$64,987 | 899,994 | +8.9% | CVI Investments, Inc. | 31 Dec 2025 |
| Orca Capital AG | 4.9% | -13% | $613,228 | -$14,002 | 362,857 | -2.2% | Orca Capital AG | 07 May 2025 |
| INTRACOASTAL CAPITAL, LLC | 5% | $537,188 | 317,863 | Mitchell P. Kopin | 06 May 2025 | |||
| ARMISTICE CAPITAL, LLC | 5% | -50% | $240,119 | +$14,019 | 142,082 | +6.2% | Armistice Capital, LLC | 31 Mar 2025 |
| STEINMAN LAWRENCE | 3.1% | $141,720 | 83,858 | Lawrence Steinman | 01 Mar 2025 |
As of 31 Dec 2025, 24 institutional investors reported holding 12,892,082 shares of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA). This represents 52% of the company’s total 24,858,270 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Squadron Capital Management LLC | 8.4% | 2,100,000 | 0% | 1.2% | $2,709,000 |
| JANUS HENDERSON GROUP PLC | 8.4% | 2,100,000 | 0% | $2,719,500 | |
| Vivo Capital, LLC | 8.4% | 2,100,000 | 0.18% | $2,709,000 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.4% | 2,100,000 | 0% | $2,709,000 | |
| AMERIPRISE FINANCIAL INC | 7.8% | 1,930,128 | 0% | $2,489,865 | |
| Cable Car Capital, LP | 2% | 500,000 | 0.04% | $645,000 | |
| ACUTA CAPITAL PARTNERS, LLC | 1.8% | 450,000 | 0.39% | $580,500 | |
| STEMPOINT CAPITAL LP | 1.4% | 355,082 | 0.08% | $458,056 | |
| AdvisorShares Investments LLC | 1.2% | 304,721 | +18% | 0.07% | $393,090 |
| Persistent Asset Partners Ltd | 1.2% | 290,555 | 0.18% | $374,816 | |
| Stonepine Capital Management, LLC | 1.1% | 275,062 | 0.28% | $354,830 | |
| VANGUARD GROUP INC | 0.39% | 97,675 | +82% | 0% | $126,000 |
| JANE STREET GROUP, LLC | 0.24% | 59,372 | +137% | 0% | $76,590 |
| CITADEL ADVISORS LLC | 0.23% | 56,183 | -17% | 0% | $72,476 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.22% | 54,495 | +114% | 0% | $70,302 |
| TWO SIGMA INVESTMENTS, LP | 0.2% | 48,773 | +36% | 0% | $62,917 |
| NORTHERN TRUST CORP | 0.11% | 28,090 | 0% | $36,236 | |
| XTX Topco Ltd | 0.08% | 20,783 | -40% | 0% | $26,810 |
| UBS Group AG | 0.05% | 13,263 | -28% | 0% | $17,109 |
| Hurley Capital, LLC | 0.01% | 3,689 | 0% | 0% | $4,759 |
| Tower Research Capital LLC (TRC) | 0.01% | 2,947 | +142% | 0% | $3,802 |
| SBI Securities Co., Ltd. | 0% | 1,051 | 0% | 0% | $1,356 |
| JPMORGAN CHASE & CO | 0% | 150 | 0% | 0% | $194 |
| BANK OF AMERICA CORP /DE/ | 0% | 63 | +8.6% | 0% | $81 |
| Virtu Financial LLC | 0% | 0 | -100% | $0 |
Institutional Holders of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 338,559 | $251,143 | +$24,321 | $0.74 | 2 |
| 2025 Q4 | 12,892,082 | $16,641,289 | +$13,193,231 | $1.29 | 24 |
| 2025 Q3 | 612,004 | $441,403 | +$224,539 | $0.73 | 18 |
| 2025 Q2 | 300,344 | $216,624 | +$151,923 | $0.72 | 10 |
| 2025 Q1 | 78,704 | $99,102 | -$116,583 | $1.30 | 7 |
| 2024 Q4 | 77,162 | $243,273 | +$214,440 | $3.15 | 7 |
| 2024 Q3 | 9,086 | $48,891 | -$103,371 | $5.42 | 6 |
| 2024 Q2 | 29,996 | $151,569 | -$300 | $5.06 | 7 |
| 2024 Q1 | 30,055 | $218,102 | +$218,102 | $7.28 | 6 |